

Lupin and Honeywell move forward jointly with plans for HFO technology in inhalers

20 May 2025 | News

Lupin is set to become first Indian company to fully integrate Honeywell's Solstice® Air in its respiratory inhalers at scale



Mumbai-based pharma major Lupin has announced its plan to use Honeywell's Solstice® Air (HFO-1234ze(E) cGMP) propellant to transform respiratory care through the development of next-generation inhalers.

Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions.

Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%. By investigating the use of this innovative, non-flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD.

"Solstice Air can play a critical role in ensuring that Lupin's respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions," said Ashish Modi, President, Honeywell India. "By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements."